Genitourinary/sexual function https://www.bioworld.com/rss en-us Travere expands rare kidney portfolio in $1B+ Everest deal http://www.bioworld.com/articles/731526 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731526-travere-expands-rare-kidney-portfolio-in-1b-everest-deal 3D illustration of kidney cross section Sun Pharma to acquire Merck spinoff Organon for $11.75B http://www.bioworld.com/articles/730787 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Sun Pharma to acquire Merck spinoff Organon for $11.75B http://www.bioworld.com/articles/730643 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Xeltis secures CE mark for Axess, its hemodialysis conduit http://www.bioworld.com/articles/730483 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730483-xeltis-secures-ce-mark-for-axess-its-hemodialysis-conduit Xeltis-Axess-vascular-access-conduit-8jan25jpg.jpg Axess vascular access conduit. Credit: Xeltis BV Travere’s Filspari approved for rare kidney disease FSGS http://www.bioworld.com/articles/730293 Tue, 14 Apr 2026 08:00:00 -0400 https://www.bioworld.com/articles/730293-traveres-filspari-approved-for-rare-kidney-disease-fsgs Kidneys, pills and chart line Highly complementary Biogen pays $5.6B; who’s jealous of Apellis? http://www.bioworld.com/articles/729963 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729963-highly-complementary-biogen-pays-56b-whos-jealous-of-apellis Handshake with charts, maps, data PKU ballyhoo averting Street’s gaze from Maze phase II AMKD win? http://www.bioworld.com/articles/729839 Wed, 25 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729839-pku-ballyhoo-averting-streets-gaze-from-maze-phase-ii-amkd-win Kidney disease illustration Kintor’s KX-826 meets phase III endpoints in alopecia http://www.bioworld.com/articles/729893 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia Alopecia - hair loss Kintor’s KX-826 meets phase III endpoints in alopecia http://www.bioworld.com/articles/729749 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729749-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia Alopecia - hair loss China approves first noninvasive therapy for cervical precancer http://www.bioworld.com/articles/729585 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729585-china-approves-first-noninvasive-therapy-for-cervical-precancer Fallopian tubes, ovaries and uterus Vertex filing BLA for ‘best-in-class’ IgAN drug on Rainier win http://www.bioworld.com/articles/729449 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729449-vertex-filing-bla-for-best-in-class-igan-drug-on-rainier-win Kidneys China approves first noninvasive therapy for cervical precancer http://www.bioworld.com/articles/729303 Wed, 04 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729303-china-approves-first-noninvasive-therapy-for-cervical-precancer Fallopian tubes, ovaries and uterus Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies http://www.bioworld.com/articles/729194 Tue, 24 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729194-innovacells-91m-tokyo-ipo-to-fund-incontinence-cell-therapies Glass yen/yuan symbol Otsuka’s IgAN therapy gets a thumbs-up from the FDA http://www.bioworld.com/articles/726792 Tue, 02 Dec 2025 00:00:00 -0500 https://www.bioworld.com/articles/726792-otsukas-igan-therapy-gets-a-thumbs-up-from-the-fda Kidneys Otsuka’s IgAN therapy gets a thumbs-up from the FDA http://www.bioworld.com/articles/726713 Wed, 26 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726713-otsukas-igan-therapy-gets-a-thumbs-up-from-the-fda Kidneys Qilu gains China rights to Laekna’s AKT inhibitor in ¥2B deal http://www.bioworld.com/articles/726370 Tue, 18 Nov 2025 12:00:00 -0500 https://www.bioworld.com/articles/726370-qilu-gains-china-rights-to-laeknas-akt-inhibitor-in-2b-deal Qilu gains China rights to Laekna’s AKT inhibitor in ¥2B deal http://www.bioworld.com/articles/726126 Wed, 12 Nov 2025 12:00:00 -0500 https://www.bioworld.com/articles/726126-qilu-gains-china-rights-to-laeknas-akt-inhibitor-in-2b-deal Up the bladder ladder, Engene tweak means phase II bell rung http://www.bioworld.com/articles/726109 Tue, 11 Nov 2025 12:00:00 -0500 https://www.bioworld.com/articles/726109-up-the-bladder-ladder-engene-tweak-means-phase-ii-bell-rung Art concept for bladder Abortion dispute active, FDA clears new generic pill http://www.bioworld.com/articles/724728 Fri, 03 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/724728-abortion-dispute-active-fda-clears-new-generic-pill CHMP recommends EU approval of Bayer’s Lynkuet for hot flashes http://www.bioworld.com/articles/724310 Fri, 19 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/724310-chmp-recommends-eu-approval-of-bayers-lynkuet-for-hot-flashes Person holding pills and glass of water Wall Street solutes phase I data from Maze in CKD, PKU http://www.bioworld.com/articles/724058 Thu, 11 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/724058-wall-street-solutes-phase-i-data-from-maze-in-ckd-pku Clinical data illustration Vor and Remegen post another phase III win http://www.bioworld.com/articles/723861 Tue, 02 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/723861-vor-and-remegen-post-another-phase-iii-win Kidney disease illustration Vor and Remegen post another phase III win http://www.bioworld.com/articles/723327 Wed, 27 Aug 2025 11:00:00 -0400 https://www.bioworld.com/articles/723327-vor-and-remegen-post-another-phase-iii-win Kidney disease illustration Apellis’ Empaveli approved in US for two rare kidney diseases http://www.bioworld.com/articles/722735 Tue, 29 Jul 2025 15:00:00 -0400 https://www.bioworld.com/articles/722735-apellis-empaveli-approved-in-us-for-two-rare-kidney-diseases Empaveli Credit: Apellis Pharmaceuticals Inc. Kintor’s KX-826 meets phase II endpoints in male alopecia http://www.bioworld.com/articles/722711 Tue, 29 Jul 2025 11:00:00 -0400 https://www.bioworld.com/articles/722711-kintors-kx-826-meets-phase-ii-endpoints-in-male-alopecia Kintor’s KX-826 meets phase II endpoints in male alopecia http://www.bioworld.com/articles/722423 Thu, 24 Jul 2025 11:00:00 -0400 https://www.bioworld.com/articles/722423-kintors-kx-826-meets-phase-ii-endpoints-in-male-alopecia Renasant launches with $54.5M to develop drugs for a genetic kidney disease http://www.bioworld.com/articles/722151 Tue, 15 Jul 2025 11:00:00 -0400 https://www.bioworld.com/articles/722151-renasant-launches-with-545m-to-develop-drugs-for-a-genetic-kidney-disease Illustration of kidney with DNA structures Prokidney produces positive phase II CKD data, thunderous stock surge http://www.bioworld.com/articles/721910 Tue, 08 Jul 2025 11:00:00 -0400 https://www.bioworld.com/articles/721910-prokidney-produces-positive-phase-ii-ckd-data-thunderous-stock-surge Kidney disease illustration Jyong’s $20M US IPO to help refile NDA of urological botanic drug http://www.bioworld.com/articles/721538 Tue, 24 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721538-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug Jyong’s $20M US IPO to help refile NDA of urological botanic drug http://www.bioworld.com/articles/721456 Wed, 18 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721456-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug